Codexis (NASDAQ:CDXS) is a biotechnology company that specializes in the discovery, development and commercialization of novel enzymes for use in pharmaceutical, food and industrial applications. Founded in 2002 and headquartered in Redwood City, California, Codexis leverages its proprietary CodeEvolver® protein engineering platform to optimize enzyme performance, specificity and stability. By applying machine learning, directed evolution and high-throughput screening, the company creates biocatalysts that enable more efficient, sustainable production processes for a broad range of end markets.
At the core of Codexis’s product offering are custom-designed enzymes that serve critical roles in active pharmaceutical ingredient (API) synthesis, small-molecule drug manufacturing and specialty chemical production. The company has commercialized multiple enzyme-enabled processes with leading pharmaceutical partners, reducing raw material use, waste generation and manufacturing costs. In addition to its pharmaceutical portfolio, Codexis develops enzymes for the food and beverage sector—such as lactose-reducing preparations for dairy products—and for consumer care and fine chemicals, demonstrating the versatility of its biocatalysis technology.
Codexis conducts research and development activities at its facilities in North America and collaborates with academic institutions, contract manufacturers and multinational corporations around the world. Its global reach includes partnerships in Europe, Asia and Latin America, where localized enzyme solutions address regional regulatory requirements and market needs. Through strategic alliances and licensing agreements, the company expands access to its enzyme innovations, integrating them into diverse supply chains and scaling production to meet customer demand.
Leadership at Codexis is headed by President and Chief Executive Officer John Nicols, who brings more than two decades of experience in biotechnology and commercial operations. Under his direction, the management team has strengthened the company’s R&D capabilities and advanced its commercial pipeline. Codexis’s board of directors and scientific advisory council include experts in molecular biology, chemical engineering and business strategy, ensuring robust governance and guiding long-term growth initiatives.
